Key Takeaways:
A biotech with $972.9 million in cash just secured a Roche partnership to attack the 40% of pancreatic cancers that share a specific genetic deletion.
IDEAYA Biosciences will combine its Phase 1 PRMT5 inhibitor IDE892 with Roche's pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic cancer, a population with no approved targeted therapies.
"This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high unmet need in PDAC," Yujiro S. Hata, president and chief executive officer of IDEAYA, said.
MTAP deletion occurs in up to 40% of pancreatic ductal adenocarcinoma cases, and nearly all of those tumors also carry RAS mutations, creating a defined molecular subgroup. IDE892 is designed as an MTA-cooperative PRMT5 inhibitor — it selectively targets cancer cells with MTAP deletion while sparing normal tissue — and has shown robust monotherapy regressions in preclinical models. Roche's RG6505 is a Phase 1 pan-RAS inhibitor targeting the downstream driver of the disease.
The collaboration gives IDEAYA access to Roche's RAS-targeting asset without ceding commercial rights to either compound. IDEAYA will sponsor the trial under joint governance, with the option to add a third drug — its own MAT2A inhibitor IDE397 — as a triplet regimen upon mutual approval. IDEAYA shares traded at $27.87, about 10% below their 200-day moving average of $30.93, after the announcement.
IDEAYA is evaluating IDE892 in a Phase 1 dose-escalation study across MTAP-deleted solid tumors and plans to launch combination cohorts in PDAC with RG6505 and in non-small cell lung cancer and other solid tumors with IDE397. The company reported $972.9 million in cash after its first-quarter 2026 results, providing runway through multiple clinical readouts.
The MTAP-deletion strategy sits at the center of IDEAYA's synthetic lethality platform. By pairing a PRMT5 inhibitor — which blocks a protein essential for cancer cell survival when the MTAP gene is missing — with a pan-RAS inhibitor that attacks the co-occurring mutation, the combination aims to hit two vulnerabilities simultaneously. No targeted therapy is currently approved for MTAP-deleted PDAC, a disease with a five-year survival rate below 10%.
For Roche, the partnership extends its early-stage RAS program into a genetically defined population without requiring its own PRMT5 asset. For IDEAYA, the collaboration provides validation from one of the largest oncology developers and a path to combination data that could differentiate IDE892 from competing PRMT5 inhibitors in development at companies including Amgen and Mirati.
This article is for informational purposes only and does not constitute investment advice.
